RKRisa Kaneshige

Risa Kaneshige

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Risa Kaneshige has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Junzo Nojima

    Department of Laboratory Science, Faculty of Health Science Yamaguchi University Graduate School of Medicine Ube Japan

    4 shared publications
  • Yukari Motoki

    Department of Laboratory Science, Faculty of Health Science Yamaguchi University Graduate School of Medicine Ube Japan

    4 shared publications
  • Junzo Nojima

    Department of Laboratory Science, Faculty of Health Science Yamaguchi University Graduate School of Medicine Ube Japan

    3 shared publications
  • Masahiro Ieko

    Affiliation Department of Nursing, Faculty of Health and Medical Sciences, Sapporo University of Health Sciences, Sapporo, Hokkaido, Japan

    3 shared publications
  • Yukari Motoki

    Department of Laboratory Science, Faculty of Health Science Yamaguchi University Graduate School of Medicine Ube Japan

    3 shared publications
  • Kenji Oku

    Affiliation Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan

    2 shared publications

Latest Publications

  • Open Access

    Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by Anticoagulants

    by Ayu Hidaka, Risa Kaneshige, Seika Nakamura, Yukari Motoki, Junzo Nojima

    Background: In Japan, clinical laboratories commonly assess lupus anticoagulant (LA) activity using phospholipid‐dependent coagulation assays as part of the diagnostic evaluation of antiphospholipid syndrome (APS). However, LA detection involves complex procedures and may yield false‐positive results in patients receiving anticoagulant therapy, such as direct oral anticoagulants (DOACs). This study aimed to clarify the effects of anticoagulants on guideline‐based LA testing (diluted Russell's viper venom time (dRVVT) and/or LA‐sensitive activated partial thromboplastin time (APTT)) and to evaluate whether they interfere with accurate LA assessment. We also explore a simple one‐step method to minimize anticoagulant interference and improve diagnostic efficiency. Methods: We developed a one‐step method for assessing LA activity by calculating the LA‐sensitivity ratio (LA‐SR), defined as the ratio of APTT measured using high‐ and low‐sensitivity APTT reagents. The clinical utility of the LA‐SR assay was evaluated using plasma samples from 57 patients with systemic lupus erythematosus, 74 patients with prolonged APTT, and DOAC‐spiked plasmas. Results: The method showed agreement with the guideline‐based LA testing. Of the 57 cases, 14 were LA‐positive and 38 were LA‐negative according to guideline‐based testing. Among the 43 cases classified as LA‐negative, five showed elevated LA‐SR values despite negative guideline‐based results. The LA‐SR assay was minimally affected by DOACs, warfarin, heparin, or coagulation factor deficiencies. Conclusion: This LA‐SR‐based method may serve as a useful screening tool for the evaluation of LA activity. A negative LA‐SR result may help identify samples unlikely to have LA activity, while positive results should be interpreted cautiously and confirmed using guideline‐based testing.

  • Open Access

    Clinical Interpretation of Platelet Activation Marker sCLEC ‐2 in Antiphospholipid Syndrome

    by Risa Kaneshige, Yukari Motoki, Kiyoshi Ichihara, Junzo Nojima

    Background: Soluble C‐type lectin‐like receptor 2 (sCLEC‐2) has emerged as a biomarker of platelet activation and thrombus formation. Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and pregnancy complications, driven in part by platelet activation. However, the clinical utility of sCLEC‐2 and the sCLEC‐2/D‐dimer ratio in APS remains unclear. Methods: Plasma samples from 19 patients with primary APS, 30 with SLE‐associated APS, 10 with SLE without APS, 40 with other collagen diseases, and 40 healthy controls ( n = 139) were analyzed. Plasma sCLEC‐2 levels and D‐dimer levels were quantified by immunoassay. Antiphospholipid antibodies (anti‐cardiolipin antibodies and anti‐β 2 ‐glycoprotein I antibodies IgG/IgM) were measured by ELISA kits. Group comparisons and correlations were evaluated. Results: Using the upper limit of the 95% CI of healthy controls as a cutoff, sCLEC‐2 positivity was observed in 100% of non‐APS autoimmune disease patients, and 98.0% of APS patients. sCLEC‐2, D‐dimer, and the sCLEC‐2/D‐dimer ratio were significantly higher in non‐APS and APS groups compared with controls ( p < 0.001). A slight but significant difference in the sCLEC‐2 and the ratio was observed between the non‐APS and APS groups. However, no significant differences were found among APS subgroups stratified by thrombosis type. sCLEC‐2 showed no correlation with any of four major antiphospholipid antibody titers. Conclusion: Although we observed raised sCLEC‐2 and sCLEC‐2/D‐dimer ratio among APS and non‐APS groups and modest differences between the two groups, clinical interpretation of the findings requires a prospective study evaluating dynamic changes of sCLEC‐2 in the clinical course.


  • Open Access

    A preliminary report on the feasibility of regression-based alignment of diagnostic thresholds for harmonized use of international classification criteria for antiphospholipid syndrome

    by Yukari Motoki, Risa Kaneshige, Yuichiro Fujieda, Kenji Oku, Eriko Morishita, Masahiro Ieko, Tatsuya Atsumi, Kiyoshi Ichihara, Junzo Nojima

    Background: In 2023, international rheumatology societies issued new classification criteria for antiphospholipid syndrome (APS). The criteria require scoring antiphospholipid antibody (aPL) titers as moderate or high using the traditional thresholds of 40U or 80U determined by “standardized” ELISA. With current popularity of non-standardized aPL assays (non-ELISA), we aimed to broaden the application of the criteria by estimating equivalent thresholds for them. Methods: Four types of aPLs (aCL/aβ2GPI-IgG/IgM) were measured using six reagents in 50 APS and 50 non-APS patients. By regression analysis of measurements between standardized ELISA and non-ELISA assays, thresholds equivalent to 10, 20, 40 and 80U were estimated for each assay. Data points below the detection limit of each assay were excluded from the regression. The diagnostic thresholds were also evaluated using “specificity-based” method described by the International Society on Thrombosis and Haemostasis (ISTH). This approach allegedly estimates diagnostic thresholds that attain predefined specificities of 0.975 and 0.995 in distinguishing APS from non-APS cases, respectively corresponding to moderate and high titers. The between-assay concordance of diagnostic classification using the estimated thresholds was calculated as kappa coefficient (κ). Results: Using major-axis regression, thresholds equivalent to the traditional units (10 − 80U) were estimated for non-ELISA assays, which led to harmonized semi-quantitative classification with high κ values. Conversely, the specificity-based method yielded thresholds that dissociated from the traditional ones, particularly for IgG-isotype assays, resulting in lower κ values than regression-based method (P = 0.0039 − 0.0098). Conclusion: The regression-based conversion of diagnostic thresholds is practical in harmonizing diagnostic classification across major aPL assays. The specificity-based method may need adjusted predefined-specificities to estimate thresholds that are equivalent to the traditional thresholds.

  • Determination of diagnostic threshold in harmonization and comparison of clinical utility for five major antiphospholipid antibody assays used in Japan

    by Risa Kaneshige, Yukari Motoki, Mika Yoshida, Kenji Oku, Eriko Morishita, Masahiro Ieko, Kiyoshi Ichihara, Junzo Nojima

    Background: Anticardiolipin antibodies (aCL) and anti‐β2‐glycoprotein I antibodies (aβ2GPI) are essential in diagnosing antiphospholipid syndrome (APS) according to the international APS guideline. Five commercial assays for aCL and aβ2GPI are available in Japan, but their test results are quite discordant. For harmonization of diagnosing APS, upper reference limit (URL) and diagnostic accuracy of each assay were evaluated and compared by testing common sets of specimens across all assays.Methods: We evaluated two manual and three automated assays for aCL and aβ2GPI of IgG‐ and IgM classes. 99%URL (the upper limit of reference interval: as per guideline) together with 97.5%URL were determined by testing sera from 198 to 400 well‐defined healthy subjects. Both URLs were compared with the cutoff values, which were determined based on ROC analysis by testing 50 each of plasma specimens from patients with/without APS. Diagnostic accuracy was evaluated as area under curve (AUC) of the ROC curve.Results: A variable degree of discrepancy between URLs and the cutoff values was observed, which was partly attributable to between‐year assay variability. 97.5%URLs were set lower and closer to the cutoff values than 99%URLs. For all assays, diagnostic accuracies of both aβ2GPI‐IgG and aCL‐IgG were generally high (AUC: 0.84−0.93); whereas those for IgM‐class assays were low (AUC: 0.57−0.67), implicating its utility is limited to rare IgG negative APS cases.Conclusion: To ensure harmonized APS diagnosis, the diagnostic thresholds of the five assays were evaluated by common procedures. Contrary to the guideline, 97.5%URL is rather recommended for diagnosing APS, which showed a closer match to the cutoff value.